Empagliflozin ameliorates diabetic cardiomyopathy via regulated branched-chain amino acid metabolism and mTOR/p-ULK1 signaling pathway-mediated autophagy

Empagliflozin ameliorates diabetic cardiomyopathy via regulated branched-chain amino acid metabolism and mTOR/p-ULK1 signaling pathway-mediated autophagy

Abstract Background Empagliflozin, a sodium–glucose co-transporter 2 inhibitor (SGLT2i), has been reported to significantly reduce the risk of heart failure in multiple clinical studies. However, the underlying mechanisms remain elusive. This study aimed to investigate the effect of empagliflozin on...

Full description

Bibliographic Details
Main Authors: Lin Zhang, Heming Zhang, Xiuzhu Xie, Ruping Tie, Xiaolin Shang, Qianqian Zhao, Junjie Xu, Liyuan Jin, Jinying Zhang, Ping Ye
Format: Article
Language:English
Published: BMC 2023-05-01
Series:Diabetology & Metabolic Syndrome
Subjects:
Empagliflozin
Diabetic cardiomyopathy
Branched-chain amino acid
Sodium–glucose co-transporter 2 inhibitor
Autophagy
Online Access:https://doi.org/10.1186/s13098-023-01061-6

Internet

https://doi.org/10.1186/s13098-023-01061-6

Similar Items